Flurizan

A Drug With Efficacy Superior to That of Memantine Would Earn up to a 50% Patient Share in the Moderate-to-Severe Alzheimer's Disease Drug Market

... over sales- leading memantine on this attribute. "Some agents, including flurizan and bapineuzumab, will be used in combination with existing drugs rather th..."Approximately one-third of the neurologists we surveyed said they will use flurizan adjunctively and nearly half of the neurologists surveyed will use bapineuz...

Flurizan in Medical Technology

Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation

...y was abandoning development of the compound for Alzheimer's disease. "While the results of the trial were certainly disappointing, just because the flurizan Phase III clinical trial failed, doesn't mean that other amyloid-targeted therapies in the clinical trial pipeline aren't valid. We learn a great deal...

Bapineuzumab To Become the First-to-Market Disease-Modifying Alzheimer's Drug After Flurizan's Discontinuation

...to launch in 2011. The recent Phase III failure of flurizan underscores the risk involved with developing an a...he reports include: -- How does the failure of flurizan impact the current Alzheimer's disease market ...nies benefit the most? -- How will the absence of flurizan change the performance of emerging therapies? ...

Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimer's ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification

...ed Start" trial design currently being used in the flurizan Phase 3 study can provide the same level of diseas...eve that this mathematical proof, coupled with the flurizan trial design may strengthen the Company's position...ut Flurizan(TM) Myriad has two Phase 3 trials of flurizan ongoing in patients with mild Alzheimer's disease....

Flurizan in Biological Technology

Flurizan's Effect in Delaying Progression From Mild Cognitive Impairment to Alzheimer's Disease is Superior to That of Aricept

... Following its Launch in 2010, Myriad Genetics' flurizan Will Earn a 23% Patient Share in the United States...ata and expert opinion shows that Myriad Genetics' flurizan has advantages in this attribute over Eisai/Pfizer...ortunity finds that, following its launch in 2010, flurizan will replace Aricept as the gold standard for mild...